Table of Content

1. Key Insights

2. Neuroendocrine Tumors Epidemiology Overview at a Glance
2.1. Market (%) Distribution of Neuroendocrine Tumors in 2017
2.2. Market (%) Distribution of Neuroendocrine Tumors in 2028

3. Disease Background and Overview: Neuroendocrine Tumors (NET)
3.1. Introduction
3.2. Classification of Neuroendocrine Tumors
3.3. Causes
3.4. Risk Factors
3.5. Symptoms
3.6. Pathophysiology
3.7. Diagnosis
3.7.1. Grading of NETs:
3.7.2. Staging of NETs:

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of NETs
4.3. Total Incident Patient Population of NETs

5. Country Wise-Epidemiology of NETs
5.1. United States
5.1.1. Total Prevalent Cases of NETs in the United States
5.1.2. Total Incident Cases of NETs in the United States
5.1.3. Diagnosed prevalent cases of NETs in the United States
5.1.4. Symptom based classification of NETs
5.1.5. Diagnosed prevalent cases based on Malignancy
5.1.6. Site-specific prevalent cases of NETs
5.1.7. Grade-wise prevalent cases of NETs
5.1.8. Stage-wise prevalent cases of NETs
5.2. EU5 Countries
5.3. Germany
5.3.1. Total Prevalent Cases of NETs in Germany
5.3.2. Total Incident Cases of NETs in Germany
5.3.3. Diagnosed prevalent cases of NETs in Germany
5.3.4. Symptom based classification of NETs
5.3.5. Diagnosed prevalent cases based on Malignancy
5.3.6. Site-specific prevalent cases of NETs
5.3.7. Grade-wise prevalent cases of NETs
5.3.8. Stage-wise prevalent cases of NETs
5.4. France
5.4.1. Total Prevalent Cases of NETs in France
5.4.2. Total Incident Cases of NETs in France
5.4.3. Diagnosed prevalent cases of NETs in France
5.4.4. Symptom based classification of NETs
5.4.5. Diagnosed prevalent cases based on Malignancy
5.4.6. Site-specific prevalent cases of NETs
5.4.7. Grade-wise prevalent cases of NETs
5.4.8. Stage-wise prevalent cases of NETs
5.5. Italy
5.5.1. Total Prevalent Cases of NETs in Italy
5.5.2. Total Incident Cases of NETs in Italy
5.5.3. Diagnosed prevalent cases of NETs in Italy
5.5.4. Symptom based classification of NETs
5.5.5. Diagnosed prevalent cases based on Malignancy
5.5.6. Site-specific prevalent cases of NETs
5.5.7. Grade-wise prevalent cases of NETs
5.5.8. Stage-wise prevalent cases of NETs
5.6. Spain
5.6.1. Total Prevalent Cases of NETs in Spain
5.6.2. Total Incident Cases of NETs in Spain
5.6.3. Diagnosed prevalent cases of NETs in Spain
5.6.4. Symptom based classification of NETs
5.6.5. Diagnosed prevalent cases based on Malignancy
5.6.6. Site-specific prevalent cases of NETs
5.6.7. Grade-wise prevalent cases of NETs
5.6.8. Stage-wise prevalent cases of NETs
5.7. United Kingdom
5.7.1. Total Prevalent Cases of NETs in the UK
5.7.2. Total Incident Cases of NETs in the UK
5.7.3. Diagnosed prevalent cases of NETs in the UK
5.7.4. Symptom based classification of NETs
5.7.5. Diagnosed prevalent cases based on Malignancy
5.7.6. Site-specific prevalent cases of NETs
5.7.7. Grade-wise prevalent cases of NETs
5.7.8. Stage-wise prevalent cases of NETs
5.8. Japan
5.8.1. Total Prevalent Cases of NETs in Japan
5.8.2. Total Incident Cases of NETs in Japan
5.8.3. Diagnosed prevalent cases of NETs in Japan
5.8.4. Symptom based classification of NETs
5.8.5. Diagnosed prevalent cases based on Malignancy
5.8.6. Site-specific prevalent cases of NETs
5.8.7. Grade-wise prevalent cases of NETs
5.9. Stage-wise prevalent cases of NETs

6. Treatment Algorithm

7. Unmet needs

8. Appendix
8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight



List of Figures


Figure 1: Classification of Neuroendocrine Tumors
Figure 2: Causes of Neuroendocrine Tumors
Figure 3: Targeting critical signaling pathways in NETs
Figure 4: Total Prevalent Population of NETs in the 7MM (2017-2028)
Figure 5: Total Incident Population of NETs in the 7MM (2017-2028)
Figure 6: Total Prevalent cases of NETs in the United States (2017-2028)
Figure 7: Total Incident cases of NETs in the United States (2017-2028)
Figure 8: Diagnosed prevalent cases of NETs in the United States (2017-2028)
Figure 9: Symptom based classification of NETs in the United States (2017-2028)
Figure 10: Diagnosed prevalent cases based on Malignancy in the United States (2017-2028)
Figure 11: Site-specific prevalent cases of NETs in the United States (2017-2028)
Figure 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
Figure 13: Stage-wise prevalent cases of NETs in the United States (2017-2028)
Figure 14: Total Prevalent cases of NETs in Germany (2017-2028)
Figure 15: Total Incident cases of NETs in Germany (2017-2028)
Figure 16: Diagnosed prevalent cases of NETs in Germany (2017-2028)
Figure 17: Symptom based classification of NETs in Germany (2017-2028)
Figure 18: Diagnosed prevalent cases based on Malignancy in Germany (2017-2028)
Figure 19: Site-specific prevalent cases of NETs in Germany (2017-2028)
Figure 20: Grade-wise prevalent cases of NETs in Germany (2017-2028)
Figure 21: Stage-wise prevalent cases of NETs in Germany (2017-2028)
Figure 22: Total Prevalent cases of NETs in the France (2017-2028)
Figure 23: Total Incident cases of NETs in the France (2017-2028)
Figure 24: Diagnosed prevalent cases of NETs in France (2017-2028)
Figure 25: Symptom based classification of NETs in France (2017-2028)
Figure 26: Diagnosed prevalent cases based on Malignancy in France (2017-2028)
Figure 27: Site-specific prevalent cases of NETs in France (2017-2028)
Figure 28: Grade-wise prevalent cases of NETs in France (2017-2028)
Figure 29: Stage-wise prevalent cases of NETs in France (2017-2028)
Figure 30: Total Prevalent cases of NETs in the Italy (2017-2028)
Figure 31: Total Incident cases of NETs in the Italy (2017-2028)
Figure 32: Diagnosed prevalent cases of NETs in Italy (2017-2028)
Figure 33: Symptom based classification of NETs in Italy (2017-2028)
Figure 34: Diagnosed prevalent cases based on Malignancy in Italy (2017-2028)
Figure 35: Site-specific prevalent cases of NETs in Italy (2017-2028)
Figure 36: Grade-wise prevalent cases of NETs in Italy (2017-2028)
Figure 37: Stage-wise prevalent cases of NETs in Italy (2017-2028)
Figure 38: Total Prevalent cases of NETs in the Spain (2017-2028)
Figure 39: Total Incident cases of NETs in the Spain (2017-2028)
Figure 40: Diagnosed prevalent cases of NETs in Spain (2017-2028)
Figure 41: Symptom based classification of NETs in Spain (2017-2028)
Figure 42: Diagnosed prevalent cases based on Malignancy in Spain (2017-2028)
Figure 43: Site-specific prevalent cases of NETs in Spain (2017-2028)
Figure 44: Grade-wise prevalent cases of NETs in Spain (2017-2028)
Figure 45: Stage-wise prevalent cases of NETs in Spain (2017-2028)
Figure 46: Total Prevalent cases of NETs in the UK (2017-2028)
Figure 47: Total Incident cases of NETs in the UK (2017-2028)
Figure 48: Diagnosed prevalent cases of NETs in the UK (2017-2028)
Figure 49: Symptom based classification of NETs in the UK (2017-2028)
Figure 50: Diagnosed prevalent cases based on Malignancy in the UK (2017-2028)
Figure 51: Site-specific prevalent cases of NETs in the UK (2017-2028)
Figure 52: Grade-wise prevalent cases of NETs in the UK (2017-2028)
Figure 53: Stage-wise prevalent cases of NETs in the UK (2017-2028)
Figure 54: Total Prevalent cases of NETs in Japan (2017-2028)
Figure 55: Total Incident cases of NETs in Japan (2017-2028)
Figure 56: Diagnosed prevalent cases of NETs in Japan (2017-2028)
Figure 57: Symptom based classification of NETs in the Japan (2017-2028)
Figure 58: Diagnosed prevalent cases based on Malignancy in Japan (2017-2028)
Figure 59: Site-specific prevalent cases of NETs in Japan (2017-2028)
Figure 60: Grade-wise prevalent cases of NETs in Japan (2017-2028)
Figure 61: Stage-wise prevalent cases of NETs in Japan (2017-2028)
Figure 62: Treatment of Neuroendocrine tumors
Figure 63: Unmet needs

 

List of Tables


Table 1: Secondary causes of nephrotic syndrome
Table 2: Systems of nomenclature for NETs
Table 3: Grading systems for NETs
Table 4: Total Prevalent Population of NETs in the 7MM (2017-2028)
Table 5: Total Incident Population of NETs in the 7MM (2017-2028)
Table 6: Total Prevalent Cases of NETs in the United States (2017-2028)
Table 7: Total Incident Cases of NETs in the United States (2017-2028)
Table 8: Diagnosed prevalent cases of NETs in the United States (2017-2028)
Table 9: Symptom based classification of NETs in the United States (2017-2028)
Table 10: Diagnosed prevalent cases based on Malignancy in the United States (2017-2028)
Table 11: Site-specific prevalent cases of NETs in the United States (2017-2028)
Table 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
Table 13: Stage-wise prevalent cases of NETs in the United States (2017-2028)
Table 14: Total Prevalent Cases of NETs in Germany (2017-2028)
Table 15: Total Incident Cases of NETs in Germany (2017-2028)
Table 16: Diagnosed prevalent cases of NETs in Germany (2017-2028)
Table 17: Symptom based classification of NETs in Germany (2017-2028)
Table 18: Diagnosed prevalent cases based on Malignancy in Germany (2017-2028)
Table 19: Site-specific prevalent cases of NETs in Germany (2017-2028)
Table 20: Grade-wise prevalent cases of NETs in Germany (2017-2028)
Table 21: Stage-wise prevalent cases of NETs in Germany (2017-2028)
Table 22: Total Prevalent Cases of NETs in France (2017-2028)
Table 23: Total Incident Cases of NETs in France (2017-2028)
Table 24: Diagnosed prevalent cases of NETs in France (2017-2028)
Table 25: Symptom based classification of NETs in France (2017-2028)
Table 26: Diagnosed prevalent cases based on Malignancy in France (2017-2028)
Table 27: Site-specific prevalent cases of NETs in France (2017-2028)
Table 28: Grade-wise prevalent cases of NETs in France (2017-2028)
Table 29: Stage-wise prevalent cases of NETs in France (2017-2028)
Table 30: Total Prevalent Cases of NETs in Italy (2017-2028)
Table 31: Total Incident Cases of NETs in Italy (2017-2028)
Table 32: Diagnosed prevalent cases of NETs in Italy (2017-2028)
Table 33: Symptom based classification of NETs in Italy (2017-2028)
Table 34: Diagnosed prevalent cases based on Malignancy in Italy (2017-2028)
Table 35: Site-specific prevalent cases of NETs in Italy (2017-2028)
Table 36: Grade-wise prevalent cases of NETs in Italy (2017-2028)
Table 37: Stage-wise prevalent cases of NETs in Italy (2017-2028)
Table 38: Total Prevalent Cases of NETs in Spain (2017-2028)
Table 39: Total Incident Cases of NETs in Spain (2017-2028)
Table 40: Diagnosed prevalent cases of NETs in Spain (2017-2028)
Table 41: Symptom based classification of NETs in Spain (2017-2028)
Table 42: Diagnosed prevalent cases based on Malignancy in Spain (2017-2028)
Table 43: Site-specific prevalent cases of NETs in Spain (2017-2028)
Table 44: Grade-wise prevalent cases of NETs in Spain (2017-2028)
Table 45: Stage-wise prevalent cases of NETs in Spain (2017-2028)
Table 46: Total Prevalent Cases of NETs in the UK (2017-2028)
Table 47: Total Incident Cases of NETs in the UK (2017-2028)
Table 48: Diagnosed prevalent cases of NETs in the UK (2017-2028)
Table 49: Symptom based classification of NETs in the UK (2017-2028)
Table 50: Diagnosed prevalent cases based on Malignancy in the UK (2017-2028)
Table 51: Site-specific prevalent cases of NETs in the UK(2017-2028)
Table 52: Grade-wise prevalent cases of NETs in the UK (2017-2028)
Table 53: Stage-wise prevalent cases of NETs in the UK (2017-2028)
Table 54: Total Prevalent Cases of NETs in Japan (2017-2028)
Table 55: Total Incident Cases of NETs in Japan (2017-2028)
Table 56: Diagnosed prevalent cases of NETs in Japan (2017-2028)
Table 57: Symptom based classification of NETs in Japan (2017-2028)
Table 58: Diagnosed prevalent cases based on Malignancy in Japan (2017-2028)
Table 59: Site-specific prevalent cases of NETs in Japan (2017-2028)
Table 60: Grade-wise prevalent cases of NETs in Japan (2017-2028)
Table 61: Stage-wise prevalent cases of NETs in Japan (2017-2028)